coronavirus vaccine after a partnership between Pfizer Inc. and BioNTech SE delivered dazzling preliminary results in a large patient trial.Regulators on both sides of the Atlantic ocean are working to speed a review of the shot’s safety and effectiveness after the data showed it prevented more than 90% of infections.
Monday’s release placed the two drugmakers firmly in the lead of the vaccine race, ahead of Moderna Inc. and AstraZeneca Plc.If the results hold up, they will leave Pfizer and BioNTech with commitments to supply hundreds of millions of doses of a vaccine to competing customers battling a virus resurgence and eager to start vaccination campaigns as soon as possible.The companies have signed advance purchase agreements for 100.